TCHP regimen

The TCHP regimen is a combination chemotherapy and targeted therapy protocol used primarily for the treatment of early-stage or locally advanced HER2-positive breast cancer. It consists of four drugs: - Docetaxel (Taxotere), a taxane-class chemotherapy that disrupts microtubule function, inhibiting cell division. - Carboplatin (Paraplatin), a platinum-based chemotherapy that causes DNA crosslinking and damage, leading to apoptosis in rapidly dividing cells. - Trastuzumab (Herceptin), a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) protein on cancer cells, blocking growth signals and promoting immune-mediated destruction. - Pertuzumab (Perjeta), another monoclonal antibody against HER2 but binding at a different site than trastuzumab; it prevents dimerization of HER2 with other receptors, further inhibiting signaling pathways involved in tumor growth. TCHP is administered intravenously every 21 days for typically six cycles as neoadjuvant therapy to shrink tumors before surgery or as adjuvant therapy after surgery to reduce recurrence risk. The regimen has demonstrated high rates of pathological complete response and favorable event-free survival outcomes in clinical studies[1][6][8]. Common side effects include anemia, mucositis, pain, diarrhea, fatigue, nausea, hair loss, and potential cardiac toxicity due to anti-HER2 agents[5][8].

Other names

docetaxel + carboplatin + trastuzumab + pertuzumabTaxotere + Paraplatin + Herceptin + PerjetaTCHP chemotherapy